AUTUMN 2026
An exciting autumn
for Auxesis Pharma
Autumn is approaching, bringing with it many exciting activities.
Throughout the summer, we at Auxesis Pharma have continued our medical development work with ASA.P® in preparation for the start of clinical studies.
We are also preparing the introduction of our new Dermatology business area, which includes skincare products.
Our work with ASA.P® has provided us with valuable experience and deeper knowledge in skincare and treatment. The results demonstrate promising opportunities to develop new products and business areas within topical treatment.
PHARMA
ASA.P®
ASA.P® remains a central part of Auxesis Pharma's pharmaceutical development. Following approval to initiate clinical studies, the work is now progressing to the next phase of development.
KERATOSES
Together with our laboratory in Lund and dermatologists, we are developing treatments for keratoses with brown and dark skin lesions, which affect more than 50 percent of the population over the age of 50.
Several potential products are under development, with clinical studies planned to begin in autumn 2027, subject to approval by the Swedish Medical Products Agency.
DERMATOLOGY
Lenvée™
During the summer, we developed Lenvée™, a restorative cream with skincare properties and certain pain-relieving properties. The product is designed for use after aesthetic treatments and when the skin barrier needs additional support.
Packaging design ahead of the launch is currently underway. Lenvée™ will be followed by complementary products planned for successive launch during 2027.
FUTURE PRODUCTS
Building on the knowledge gained from ASA.P®, we are developing new products for skin well-being in consultation with leading dermatologists.
Lenvée™ –
planned launch in 2027
The product is a rich, restorative cream developed under the guidance of leading dermatologists for use after aesthetic treatments and during periods when the skin barrier needs additional support.
The product also has certain pain-relieving properties, which align well with Auxesis Pharma's values and overall mission.
2026 – ASA.P®
Next step towards clinical studies
→Q1–Q2 2027
Planned launch of Lenvée™ within Dermatology
→2027
Successive launch of complementary dermatology products
→AUTUMN 2027
Planned start of clinical studies for keratosis treatments
(Pharma)